MilliporeSigma, Merck KGaA’s life science service provider, is teaming with the University of Oxford’s vaccine-focused research body, the Jenner Institute, to develop more cost-effective vaccine ...
AUSTIN, Texas, Dec. 13 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN) announced today that it has been granted a broad patent by the European ...
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has ...
OXGENE describes how self-silencing adenoviral vectors can deliver high-quality, high-titer AAV and even grow AAV from AAV Until very recently, adeno-associated virus (AAV) had an excellent safety ...
Gene and modified cell therapies (for example, chimeric antigen receptor [CAR] T-cell therapies) in early to late clinical development are showing significant promise to treat and potentially cure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results